According to the agreements entered into between the parties, a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of $293 million.
Hester Biosciences recently posted its Q2 and H1FY18 results. Net sales for Q2FY18 is recorded at Rs 38.48 crore as compared to Rs 30.17 crore for the previous corresponding period, thereby registering a growth of 27.53 per cent.